Brad G Smith1, Jan S Lewin. 1. Department of Head and Neck Surgery, Section of Speech-Language Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. bradgsmith@mdanderson.org
Abstract
PURPOSE OF REVIEW: Head and neck lymphedema (HNL) is a common and often debilitating cancer treatment effect that is under-researched and ill defined. We examined current literature and reviewed historical treatment approaches. We propose a model for evaluation and treatment of HNL used at The University of Texas M. D. Anderson Cancer Center (MDACC) for patients with head and neck cancer (HNC). RECENT FINDINGS: Despite the morbidity associated with HNL in patients with HNC, to our knowledge, no article has been published within the past 18 months whose primary focus is HNL. Eight publications included HNL but only as a secondary focus related to treatment effect, risk of dysphagia, prognostic indicator of underlying disease, and quality of life. A potential benefit of selenium treatment to reduce HNL was reported. SUMMARY: This article highlights the recent literature regarding HNL in patients treated for HNC. Although HNL is reported as a potential complication of HNC treatment, no clear definition of the disease or its management are published. Our early experience using an objective evaluation and treatment protocol holds promise for a better understanding of HNL in patients treated for head and neck malignancy.
PURPOSE OF REVIEW: Head and neck lymphedema (HNL) is a common and often debilitating cancer treatment effect that is under-researched and ill defined. We examined current literature and reviewed historical treatment approaches. We propose a model for evaluation and treatment of HNL used at The University of Texas M. D. Anderson Cancer Center (MDACC) for patients with head and neck cancer (HNC). RECENT FINDINGS: Despite the morbidity associated with HNL in patients with HNC, to our knowledge, no article has been published within the past 18 months whose primary focus is HNL. Eight publications included HNL but only as a secondary focus related to treatment effect, risk of dysphagia, prognostic indicator of underlying disease, and quality of life. A potential benefit of selenium treatment to reduce HNL was reported. SUMMARY: This article highlights the recent literature regarding HNL in patients treated for HNC. Although HNL is reported as a potential complication of HNC treatment, no clear definition of the disease or its management are published. Our early experience using an objective evaluation and treatment protocol holds promise for a better understanding of HNL in patients treated for head and neck malignancy.
Authors: C Paul van Wilgen; Pieter U Dijkstra; Berend F A M van der Laan; John T Plukker; Jan L N Roodenburg Journal: Head Neck Date: 2004-09 Impact factor: 3.147
Authors: Ming-Huang Chen; Peter Mu-Hsin Chang; Po-Min Chen; Cheng-Hwai Tzeng; Pen-Yuan Chu; Shyue-Yih Chang; Muh-Hwa Yang Journal: Support Care Cancer Date: 2009-10-12 Impact factor: 3.603
Authors: Jie Deng; Barbara A Murphy; Mary S Dietrich; Robert J Sinard; Kyle Mannion; Sheila H Ridner Journal: Support Care Cancer Date: 2015-08-29 Impact factor: 3.603
Authors: Judith A E M Zecha; Judith E Raber-Durlacher; Raj G Nair; Joel B Epstein; Sharon Elad; Michael R Hamblin; Andrei Barasch; Cesar A Migliorati; Dan M J Milstein; Marie-Thérèse Genot; Liset Lansaat; Ron van der Brink; Josep Arnabat-Dominguez; Lisette van der Molen; Irene Jacobi; Judi van Diessen; Jan de Lange; Ludi E Smeele; Mark M Schubert; René-Jean Bensadoun Journal: Support Care Cancer Date: 2016-03-17 Impact factor: 3.603
Authors: Sheila H Ridner; Mary S Dietrich; Kenneth Niermann; Anthony Cmelak; Kyle Mannion; Barbara Murphy Journal: Lymphat Res Biol Date: 2016-06-15 Impact factor: 2.589
Authors: Brad G Smith; Katherine A Hutcheson; Leila G Little; Roman J Skoracki; David I Rosenthal; Stephen Y Lai; Jan S Lewin Journal: Otolaryngol Head Neck Surg Date: 2014-11-11 Impact factor: 3.497
Authors: Simona F Shaitelman; Kate D Cromwell; John C Rasmussen; Nicole L Stout; Jane M Armer; Bonnie B Lasinski; Janice N Cormier Journal: CA Cancer J Clin Date: 2014-11-19 Impact factor: 508.702
Authors: Leanne K Jackson; Sheila H Ridner; Jie Deng; Carmin Bartow; Kyle Mannion; Ken Niermann; Jill Gilbert; Mary S Dietrich; Anthony J Cmelak; Barbara A Murphy Journal: J Palliat Med Date: 2016-05-26 Impact factor: 2.947